Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke - PubMed (original) (raw)

Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke

Li Hong Shen et al. J Cereb Blood Flow Metab. 2007 Jan.

Abstract

Bone marrow stromal cells (BMSCs) facilitate functional recovery in rats after stroke when administered acutely (1 day) or subacutely (7 days). In this study, we postponed the time of cell transplantation to 1 month after stroke. Female retired breeder rats were subjected to 2 h of middle cerebral artery occlusion (MCAo). Male BMSCs (3 x 10(6)) or phosphate-buffered saline were administered intravenously, and the animals were killed 3 months later. An additional population of nontreated rats was killed at 1 month after MCAo. Significant recovery of behavior was found in BMSC-treated rats beginning at 1 month after cell injection in the modified neurologic severity score test and the adhesive-removal test compared with control animals (P<0.05). In situ hybridization showed that BMSCs survived and preferentially localized to the ipsilateral hemisphere. Double staining revealed that approximately 13% and 6% Y-chromosome-positive cells expressed the astrocyte marker, glial fibrillary acidic protein, and the neuronal marker, microtubule-associated protein-2, respectively. In addition, BMSC treatment reduced scar thickness, and increased the number of proliferating cells and oligodendrocyte precursor cells along the subventricular zone in the ipsilateral hemisphere. Expression of the chemokine stromal-cell-derived factor-1 (SDF-1) was significantly increased along the ischemic boundary zone compared with the corresponding areas in the contralateral hemisphere at 1 month and 4 months (P<0.01) after stroke. The SDF-1 receptor, CXC-chemokine receptor-4 (CXCR4), was expressed in BMSCs both in vitro and in vivo. Our data show that the time window of BMSC therapy is at least 1 month after stroke; the interaction of SDF-1/CXCR4 may contribute to the trafficking of transplanted BMSCs.

PubMed Disclaimer

Cited by

Therapeutic potential of mesenchymal stem cells for cerebral small vessel disease.
Chen DH, Huang JR, Su SL, Chen Q, Wu BY. Chen DH, et al. Regen Ther. 2024 Feb 22;25:377-386. doi: 10.1016/j.reth.2023.11.002. eCollection 2024 Mar. Regen Ther. 2024. PMID: 38414558 Free PMC article. Review.
EPO regulates the differentiation and homing of bone marrow mesenchymal stem cells through Notch1/Jagged pathway to treat pulmonary hypertension.
Li K, Shen C, Wen N, Han Y, Guo L. Li K, et al. Heliyon. 2024 Feb 7;10(4):e25234. doi: 10.1016/j.heliyon.2024.e25234. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38375306 Free PMC article.
Intracerebral Transplantation of Autologous Mesenchymal Stem Cells Improves Functional Recovery in a Rat Model of Chronic Ischemic Stroke.
Myers MI, Hines KJ, Gray A, Spagnuolo G, Rosenwasser R, Iacovitti L. Myers MI, et al. Transl Stroke Res. 2023 Nov 2. doi: 10.1007/s12975-023-01208-7. Online ahead of print. Transl Stroke Res. 2023. PMID: 37917400
Effects of the Co-Overexpression of the BCL and BDNF Genes on the Gamma-Aminobutyric Acid-Ergic Differentiation of Wharton's-Jelly-Derived Mesenchymal Stem Cells.
Borkowska P, Morys J, Zielinska A, Kowalski J. Borkowska P, et al. Biomedicines. 2023 Jun 18;11(6):1751. doi: 10.3390/biomedicines11061751. Biomedicines. 2023. PMID: 37371846 Free PMC article.
Research hotspots and frotiers of stem cells in stroke: A bibliometric analysis from 2004 to 2022.
Zhang Q, Zeng Y, Zheng S, Chen L, Liu H, Chen H, Zhang X, Zou J, Zheng X, Wan Y, Huang G, Zeng Q. Zhang Q, et al. Front Pharmacol. 2023 Mar 3;14:1111815. doi: 10.3389/fphar.2023.1111815. eCollection 2023. Front Pharmacol. 2023. PMID: 36937837 Free PMC article.

Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke - PubMed (original) (raw)